CX Institutional Makes New $31,000 Investment in Becton Dickinson and Co (NYSE:BDX)

CX Institutional bought a new position in Becton Dickinson and Co (NYSE:BDX) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 124 shares of the medical instruments supplier’s stock, valued at approximately $31,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. TRUE Private Wealth Advisors bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $25,000. Allworth Financial LP increased its holdings in shares of Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 85 shares during the last quarter. Hexavest Inc. bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $28,000. Lipe & Dalton bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $28,000. Finally, Mcmillion Capital Management Inc. bought a new position in shares of Becton Dickinson and in the 2nd quarter worth $40,000. Institutional investors and hedge funds own 84.21% of the company’s stock.

A number of equities analysts have recently commented on BDX shares. Wells Fargo & Co increased their price target on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies decreased their price target on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Morgan Stanley increased their price target on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Finally, Raymond James increased their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a report on Friday, June 28th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $266.55.

In related news, Director Claire Fraser sold 1,429 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP James C. Lim sold 9,299 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $263.53, for a total transaction of $2,450,565.47. Following the transaction, the executive vice president now directly owns 33,041 shares in the company, valued at approximately $8,707,294.73. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,249 shares of company stock worth $9,616,803. 0.12% of the stock is owned by insiders.

BDX stock opened at $252.86 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The firm’s fifty day moving average is $253.69 and its 200 day moving average is $245.85. The firm has a market cap of $66.90 billion, a P/E ratio of 22.97, a P/E/G ratio of 1.58 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same quarter last year, the firm earned $2.91 EPS. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, analysts forecast that Becton Dickinson and Co will post 11.68 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.22%. The ex-dividend date of this dividend was Friday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.